SCHEMBL3933827

SCHEMBL3933827

NCC(=O)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.48
MAPT P10636 4/20 0.48
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
KMT2A Q03164 4/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.46
PSEN1 P49768 3/20 0.45
PSEN2 P49810 3/20 0.45
APH1B Q8WW43 3/20 0.45
NCSTN Q92542 3/20 0.45
APH1A Q96BI3 3/20 0.45
PSENEN Q9NZ42 3/20 0.45
ALDH1A1 P00352 4/20 0.44
PTGES2 Q9H7Z7 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663503 0.81 MAPT (0.51) FBP1MAPTKMT2AHTTMEN1
SCHEMBL194745 0.80 MAPT (0.53) FBP1MAPTKMT2AHTTMEN1
SCHEMBL3933822 0.79 FBP1 (0.49) FBP1MAPTKMT2AHTTMEN1
SCHEMBL682128 0.78 MAPT (0.63) FBP1MAPTKMT2AHTTMEN1
SCHEMBL265540 0.75 FBP1 (0.52) FBP1MAPTKMT2AHTTMEN1
SCHEMBL19341771 0.74 MAPT (0.51) FBP1MAPTKMT2AHTTMEN1
SCHEMBL195598 0.74 P2RY12 (0.53) FBP1MAPTKMT2AHTTMEN1
SCHEMBL2012755 0.74 KMT2A (0.56) FBP1MAPTKMT2AHTTMEN1
SCHEMBL4207122 0.73 KMT2A (0.53) MAPTKMT2AHTTMEN1SMN1; SMN2
SCHEMBL8230214 0.73 KMT2A (0.53) FBP1MAPTKMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258847-A1 Cholanic Acid Amides NOVARTIS AG (CH) 2009-10-15 US claimed
EP-2044100-A2 SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS Novartis AG (CH) 2009-04-08 EP claimed
WO-2008009407-A2 SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS NOVARTIS AG (CH) 2008-01-24 WO claimed
US-20090258847-A1 Cholanic Acid Amides NOVARTIS AG (CH) 2009-10-15 US disclosed
EP-2044100-A2 SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS Novartis AG (CH) 2009-04-08 EP disclosed
WO-2008009407-A2 SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS NOVARTIS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258847-A1 Cholanic Acid Amides NR1H4, SLC10A1, CYP46A1 FBP1 3495/4885MAPT 2776/4885CA1 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.